Are you looking for penny stocks to add to your watch list? You’re not alone and there are plenty of cheap stocks to choose from. If you are looking at some of the most popular penny stocks today, you might’ve come across Graybug Vision, Inc (NASDAQ: GRAY), Revelation Biosciences Inc. (NASDAQ: REVB), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), and Bark Inc. (NYSE: BARK). Whether you’re looking for low float penny stocks or stocks with high short interest, these stocks seem to have a few points of interest from the retail trading market today.
There’ve been many different daily trends in the stock market, especially for small- & micro-cap stocks. One of the more prevalent in the stock market today is coming from low float penny stocks. We discuss a few in the article 3 Low Float Penny Stocks To Watch After KSPN Stock Explodes 180%.
Hot Penny Stocks To Watch
In addition to the technical, there are some fundamentals to keep track of. We’ll look at a few simple technical analysis points, including moving averages and daily volume. If you’re interested in additional charting strategies, you can check out some of these great articles on PennyStocks.com:
- Buy Penny Stocks Like Hedge Funds Do: A How-To Guide
- Trading Penny Stocks & Using Volume Analysis To Find Stocks To Buy
- Top Penny Stocks Trading Strategies in 2022
- 4 Reasons You’re Not Making Money With Penny Stocks
- 10 Secret Ways To Find The Best Penny Stocks To Buy In 2022
- Penny Stock Chart Patterns Every Trader Should Know [Top 5]
This article looks at a handful of popular penny stocks to watch today after recent catalysts have placed a bright spotlight on them in August.
Graybug Vision, Inc. (NASDAQ: GRAY)
If you’re an avid reader of PennyStocks.com content then Graybug Vision is no stranger to you. We discussed it at the end of June as one of the penny stocks to watch for July 2022. Since then, GRAY stock remained in a tight channel until this week.
As a refresher, Graybug reported lackluster earnings but emphasized its focus on advancing its pipeline treatments. Management highlighted GB-102 as a potential wet-AMD drug candidate being developed for an additional Phase 2 trial to further evaluate its safety and efficacy. It also holds a pipeline of gene therapies targeting rare vision-threatening diseases.
[Read More] Best Penny Stocks To Buy? 4 To Watch Right Now
While it pursues strategic alternatives, new developments have come about. The latest was a US Patent granted to the company. It’s titled “Equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates” and geared toward retina, neuronal or neurodegenerative diseases. This came to light after it was posted directly on the USPTO website and not discussed by the company (so far). As traders continue circulating the patent, speculation has placed GRAY stock back in focus at the beginning of August.
Revelation Biosciences Inc. (NASDAQ: REVB)
Another one of the companies we’ve discussed previously is Revelation Biosciences. The company has developed multiple platforms for immunologic-based therapies. It recently announced a $5 million financing to further develop its REVTx-99b, REVTx-200, and REVTx-300 treatment candidates.
Its lead candidate, REVTx-99b was a recent highlight after data was released on July 22nd. The primary endpoint to evaluate the effects of REVTx-99b versus placebo on safety and tolerability was met. Now the plan is to assess the treatment candidate further.
While not much more discussion was had, REVB stock remains a focus for retail traders in the stock market today. With fresh capital in hand, eyes are on the next phase of R&D for its immunologic portfolio.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH)
Low float penny stocks, short squeeze penny stocks, and penny stocks under $1 have become frequent themes to follow. In Reviva’s case, the sub-$1 category is helping it gain some attention in the stock market today. Shares of RVPH stock ripped higher on Tuesday, reaching $0.75 on some of the highest trading volumes of the year.
Ever since a late-July clinical update, there’ve been some concerns over the future prospects of the company. Namely, Reviva discussed evaluating certain efforts in other chronic neuropsychiatric and pulmonary indications besides schizophrenia. Its Brilaroxazine has a wide range of potential indications, according to the company.
These include bipolar disorder, major depressive disorder, ADHD, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Meanwhile, the company explained that it’s seeking additional capital to explore these additional indications. The interesting part of that is in the same week as the operations update, Reviva terminated its At the Market Offering agreement with HC Wainwright that would’ve allowed it to sell up to $12.9 million worth of RVPH stock. As a result, analysts like those at Maxim lowered their price target (to $3 from $5) but maintained a Buy rating.
With this backdrop, RVPH stock has managed to make an about-face recently, and Tuesday’s action is much more bullish without any direct headline catalyst so far.
Bark Inc. (NYSE: BARK)
It’s earnings season, which means a different kind of risk/reward. Retail stocks have flip-flopped over the last few weeks with a mixed bag of results. Some are beating expectations, others are slashing guidance with stark reactions in the market. Bark Inc. is in this boat as it’s set to report the next round of quarterly results after the closing bell on Tuesday.
The company is one of the household name penny stocks we’ve discussed over the last few months. It was only until the end of July that BARK stock saw a brief reprieve from nearly 7 months of a slow bleed in the market. The company offers themed toy and treat subscription services for pets via lines including BarkBox, Bark Eats, and Bark Bright.
Investors will surely look to see if the “ruff” Q1 earnings will subside in Q2. Furthermore, in another few days, BARK stock could be on the radar as it’s set to present at the Canaccord Genuity Growth Conference on the 11th. Just keep in mind that earnings could dictate the pace of BARK stock, good or bad and presents a higher risk profile especially right now.